A randomized open-label study comparing the safety and efficacy of Ritonavir boosted Lopinavir and 2-3N(t)RTI backbone versus Ritonavir boosted Lopinavir and Raltegravir in participants virologically failing first-line NNRTI/2N(t)RTI therapy: the SECOND-LINE study

Project no.: HIV-NAT 119/SECONDLINE

This is a Phase IIIb/IV, international, randomized, open label study comparing two regimens of combination antiretroviral therapy in people living with HIV with confirmed virological failure of first-line NNRTI/2N(t)RTI regimens. The study runs for 96 weeks but the primary analysis takes place at the week 48.